Abstract
Intensive high-dose chemotherapy with autologous stem-cell support has become a common treatment strategy for non-Hodgkin's lymphomas. A cost-identification analysis was conducted comparing 10 patients autografted with PBSC to 10 others autografted with BM. The analysis included harvest and graft until graft day +100 and was carried out from the point of view of the hospital setting. Resources used, logistic and direct medical costs per patient were identified, and sensitivity analyses performed. The cost distribution was different. Stem cell harvest was more expensive for PBPC ($9030) and BM ($4745); on the other hand, hospitalization from graft to discharge from hospital cost savings with PBSC were about $10666. After discharge from hospital, costs were similar and cheaper in both groups. For the overall study the PBPC procedure was less expensive than ABMT, $35381 and $41759 respectively, with cost savings of $6378. The number of days spent in hospital and blood bank costs were the major cost factors. This study was based on a single pathology, non-Hodgkin's lymphoma, and the actual hospital records for each patient situation as opposed to a clinical trial, and our results were consistent with different previous studies carr...Continue Reading
Citations
Nov 30, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S LimatUNKNOWN Groupe Ouest Est d'étude des Leucémies et Autres Maladies du Sang (GOELAMS)
Sep 11, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M van AgthovenC A Uyl-de Groot
Feb 22, 2002·Critical Reviews in Oncology/hematology·Gian Luigi Cetto, Annamaria Molino
Sep 21, 2006·International Journal of Technology Assessment in Health Care·Panos KanavosCostantina Politis
Aug 12, 1999·British Journal of Haematology·J SweetenhamS Townshend
Feb 21, 2004·PharmacoEconomics·Stephen M BeardFiona Sampson
Jan 31, 2009·PharmacoEconomics·Philippe FagnoniUNKNOWN Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang
Mar 15, 2014·Frontiers of Medicine·Muhammad FurqanDelong Liu
Jun 7, 2014·Cell Biochemistry and Biophysics·Xin LiQi Yu
Jul 16, 2003·Leukemia Research·Akiko YashimaTomoyuki Masuda
Dec 2, 2004·Expert Opinion on Pharmacotherapy·Michel van AgthovenAnton Hagenbeek
May 18, 2011·Transfusion·Chitra HosingUday Popat
May 21, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul ShaughnessySimon Pickard
Oct 22, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sergio GiraltSteven Devine
Dec 4, 2015·Iranian Journal of Cancer Prevention·Nahid HatamAbdosaleh Jafari
May 13, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sandhya R PanchDavid F Stroncek
May 9, 2000·Bone Marrow Transplantation·S LimatJ Y Cahn
Aug 31, 2002·Bone Marrow Transplantation·M van AgthovenR Willemze
Jul 5, 2001·Bone Marrow Transplantation·L De RosaL Pescador
Jan 20, 2007·International Journal of Technology Assessment in Health Care·Frida KastengJonas Lundkvist
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J D RizzoE B Bass
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S J LeeJ H Antin
Aug 27, 2019·Hematology/oncology and Stem Cell Therapy·M AljurfD Niederwieser